Posts By :

michael

Lysogene communique une mise à jour sur l’étude AAVance qui évalue le LYS-SAF302 chez les patients atteints de MPS IIIA
Lysogene communique une mise à jour sur l’étude AAVance qui évalue le LYS-SAF302 chez les patients atteints de MPS IIIA 150 150 Lysogene

PARIS, France – le 15 octobre 2020 à 08h00 – Lysogene (FR0013233475 – LYS), société…

Lysogene provides update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA
Lysogene provides update on the AAVance Clinical Trial Evaluating LYS-SAF302 in Patients with MPS IIIA 150 150 Lysogene

PARIS, France – 15 October 2020 at 08:00am – Lysogene (FR0013233475 – LYS), a Phase…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2020 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

Start Typing